Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.15
$0.109.52%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -12.52% | -40.62% | -4.72% | -30.39% | 4.88% |
| Total Depreciation and Amortization | 4.86% | 28.57% | 8.74% | -4.63% | 0.93% |
| Total Amortization of Deferred Charges | 126.37% | 3.02% | -23.19% | 58.99% | 40.91% |
| Total Other Non-Cash Items | -92.53% | 11.71% | 4.40% | 23.53% | -6.50% |
| Change in Net Operating Assets | 207.32% | 173.61% | -166.67% | 433.95% | 133.30% |
| Cash from Operations | -9.19% | -20.57% | -46.57% | -10.96% | 20.40% |
| Capital Expenditure | 40.29% | 43.95% | 80.10% | -31,050.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 47.30% | -703.43% | -51.45% | 132.93% | -465.59% |
| Cash from Investing | 47.29% | -716.95% | -49.98% | 131.32% | -465.62% |
| Total Debt Issued | -100.00% | -- | -- | 10,127.71% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -1,207.94% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.11% | 23,036.29% | -103.31% | -73.51% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -206.40% | 474.90% | -173.95% | 1,151.64% | 93.13% |